Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(9), P. 844 - 862
Published: May 4, 2024
Language: Английский
EClinicalMedicine, Journal Year: 2024, Volume and Issue: 73, P. 102655 - 102655
Published: May 31, 2024
Janus kinase (JAK) inhibition is a promising approach for treating vitiligo. We aimed to assess the efficacy and safety of upadacitinib, an oral selective JAK inhibitor, in adults with non-segmental
Language: Английский
Citations
12
Advanced Science, Journal Year: 2024, Volume and Issue: 11(31)
Published: June 17, 2024
Abstract Vitiligo is an autoimmune disease characterized by epidermal melanocyte destruction, with abnormal responses and excessive oxidative stress as two cardinal mechanisms. Human umbilical mesenchymal stem cells‐derived exosomes (hUMSCs‐Exos) are regarded promising therapeutic choice for diseases due to potent immunosuppressive anti‐oxidative properties, which can be potentiated under 3D cell culture condition. Nevertheless, whether derived from spheroids of hUMSCs (3D‐Exos) exhibit considerable effect on vitiligo the underlying mechanism remain elusive. In this study, systemic administration 3D‐Exos showed a remarkable in treating mice vitiligo, revealed ameliorated skin depigmentation, less CD8 + T cells infiltration, expanded Treg skin, exerted better than 2D‐Exos. Mechanistically, prominently facilitate expansion lesion suppress H 2 O ‐induced melanocytes apoptosis. Forward miRNA profile analysis molecular experiments have demonstrated that miR‐132‐3p miR‐125b‐5p enriched greatly contributed these biological effects targeting Sirt1 Bak1 respectively. aggregate, efficiently ameliorate simultaneously potentiating cells‐mediated immunosuppression suppressing stress‐induced damage via delivery miR‐125b‐5p. The employment will treament vitiligo.
Language: Английский
Citations
11
Journal of Dermatological Science, Journal Year: 2024, Volume and Issue: 113(3), P. 86 - 92
Published: Jan. 11, 2024
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids tacrolimus have been used as topical treatments. Recently, novel agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, emerged. Ruxolitinib the first approved in vitiligo therapy. Furthermore, ritlecitinib currently under clinical trials for oral treatment active vitiligo. In this review, we discuss possibility JAK inhibitors promising options with regard to their mechanism action, efficacy safety.
Language: Английский
Citations
10
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 4, 2024
Vitiligo is an autoimmune disease that leads to disfiguring depigmented lesions of skin and mucosa. Although effective treatments are available for vitiligo, there still some patients with poor responses conventional treatment. Refractory vitiligo mostly located on exposed sites such as acral lips, leading significant life stress. Understanding the causes refractory developing targeted essential enhance outcomes. In this review, we summarized recent treatment approaches potential methods vitiligo. Janus kinase inhibitors have shown efficacy in A variety surgical interventions fractional carbon dioxide laser been widely applied combination therapies. Furthermore, melanocyte regeneration activation therapies potentially strategies. Patients should be referred psychological monitoring reduce pathogenic effects chronic Finally, depigmentation camouflage may beneficial achieving uniform color improved quality life. Our ultimate focus provide alternative options bring inspiration future research.
Language: Английский
Citations
9
Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(9), P. 844 - 862
Published: May 4, 2024
Language: Английский
Citations
9